HilleVax, Inc. (HLVX)

Market Cap	90.78M
Revenue (ttm)	n/a
Net Income (ttm)	-106.50M
Shares Out	49.61M
EPS (ttm)	-2.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,672
Open	1.840
Previous Close	1.860
Day's Range	1.825 - 1.850
52-Week Range	1.340 - 15.600
Beta	0.77
Analysts	Hold
Price Target	2.33 (+27.32%)
Earnings Date	May 8, 2025

About HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2022
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: HLVX
• Website: https://www.hillevax.com

Analyst Forecast

According to 5 analysts, the average rating for HLVX stock is "Hold." The 12-month stock price forecast is $2.33, which is an increase of 27.32% from the latest price.

Price Target

$2.33

(27.32% upside)

Analyst Consensus: Hold